Selumetinib granted orphan drug designation in Japan for neurofibromatosis type 1

AstraZeneca today announced that selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1), a rare and debilitating genetic disease.
Läs mer